Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 31 news outlets
blogs: 5 blogs
policy: 1 policy source
twitter: 364 X users
facebook: 1 Facebook page
wikipedia: 4 Wikipedia pages

reddit: 2 Redditors
f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 9 clinical guideline sources
podcasts: 5 podcasts

Readers on

mendeley: 246 Mendeley

So far, Altmetric has seen 8 posts from 5 blogs.

Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

Cancer Currents: An NCI Cancer Research Blog, 21 May 2024

In a large clinical trial, treatment with pembrolizumab after surgery helped people with kidney cancer live longer than those…

#VisualAbstract: Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Physician's Weekly, 04 May 2024

1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with an HR 0.62 (signifi…

Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Physician's Weekly, 23 Apr 2024

1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with an HR 0.62 (signifi…

30-month follow-up analysis of a RCT | Pembrolizumab vs. placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma.

SPECIALTIES, 05 Sep 2022

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 4 additional blog posts.